Versant Venture Management’s Contineum Therapeutics CTNM Stock Holding History

Versant Venture Management’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.09M	Hold	542,628	–	–	5.01%	5
2025 Q4	$6.2M	Hold	542,628	–	–	4.11%	5
2025 Q3	$6.38M	Hold	542,628	–	–	3%	6
2025 Q2	$2.15M	Sell	542,628 -375,535	-41%	-$1.63M	2.62%	6
2025 Q1	$6.41M	Hold	918,163	–	–	10.64%	3
2024 Q4	$13.5M	Hold	918,163	–	–	15.51%	3
2024 Q3	$17.6M	Hold	918,163	–	–	27.64%	2
2024 Q2	$16.2M	Buy	+918,163	New	+$14.8M	20.92%	2

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Versant Venture Management's CTNM Position: Q1 2026 in Review

Versant Venture Management held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 542,628 shares worth $7.09M. The position accounts for 5.01% of the portfolio, ranked #5.

Versant Venture Management first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $17.6M in Q3 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

Versant Venture Management held 542,628 shares of Contineum Therapeutics worth $7.09M as of Q1 2026.
Versant Venture Management left its Contineum Therapeutics share count unchanged in Q1 2026.
Contineum Therapeutics made up 5.01% of Versant Venture Management's portfolio in Q1 2026, its #5 holding.
Versant Venture Management first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
Versant Venture Management's Contineum Therapeutics position peaked at $17.6M in Q3 2024.
90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Versant Venture Management's 13F filing for Q1 2026, filed 5 May 2026.